Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PacificHealth's Q2 revenues up 15 percent

This article was originally published in The Tan Sheet

Executive Summary

Sports nutrition firm PacificHealth Laboratories experienced a 15 percent revenue boost in its second quarter of 2009 with a jump to $2.7 million from $2.3 million in the comparative 2008 quarter, the firm says in its July 29 earning call. Sales and marketing spend jumped $209,436 or 85 percent for the quarter mostly due to increased public relations and marketing for its recently launched weight-management product ForzeGPS (1"The Tan Sheet" July 6, 2009). Gross profit for the quarter inched up to $1.3 million from $1.1 million in the year-ago period. President and CEO Jason Ash said the Matawan, N.J., firm is optimistic its reported growth can be built upon and that its new product launch and marketing strategies have "resulted in a solid start to our third quarter.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103215

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel